T MART 20MG TABLET is used to manage essential hypertension. It contains Telmisartan which belongs to the group of medicines called Angiotensin II receptor antagonists. It is also used to reduce the risk of cardiovascular events such as heart attack or stroke in adults who are known to have a reduced or blocked blood supply to the heart or legs and had a stroke or with a high risk of diabetes. T MART 20MG TABLET makes blood vessels to relax and thus lowers the blood pressure by blocking the effects of Angiotensin II (substance produced in your body which causes narrowing of blood vessels).
Your doctor may check the kidney function test, blood pressure and the amount of electrolytes (Ex. potassium) in body prior to the management or at regular intervals during management with this medicine. T MART 20MG TABLET is not recommended for use in patients having severe liver problems such as cholestasis or biliary obstruction (flow of bile from liver stops or slows). T MART 20MG TABLET should be used with caution in patients having diabetes, kidney disease, heart problems and raised aldosterone levels.
T MART 20MG TABLET is not recommended for use in early pregnancy and must not be taken by women who are pregnant for more than 3 months and it is not recommended for use in breastfeeding women. T MART 20MG TABLET is not recommended for use in children and adolescents (up to the age of 18 years) and it should be used with caution in elderly patients (aged 65 years and above). The most common side effect of taking T MART 20MG TABLET is low blood pressure. Consult your doctor if the side effects worsen or persists for a longer period.
It is used to:
T MART 20MG TABLET makes blood vessels to relax and thus lowers the blood pressure by blocking the effects of Angiotensin II (substance produced in your body which causes narrowing of blood vessels).
Stop taking T MART 20MG TABLET and contact your doctor immediately if you experience any of the following side effects:
T MART 20MG TABLET is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to the baby if used after 3 months of pregnancy.
T MART 20MG TABLET is not recommended for use in breastfeeding women. Your doctor may choose another management especially if you want to breast-feed when your baby is new-born or born prematurely.
Do not drive or operate any machines if you feel dizzy or tired after taking T MART 20MG TABLET.
Avoid consumption of alcohol as it may increase the risk of low blood pressure.
T MART 20MG TABLET should be taken with caution in patients with kidney disease, kidney artery stenosis (narrowing of blood vessels to one or both the kidneys) and with a history of kidney transplant.
T MART 20MG TABLET is not recommended for use in patients with severe liver problems such as cholestasis or biliary obstruction (flow of bile from liver stops or slows). T MART 20MG TABLET should be used with caution in patients with liver diseases.
Do not take T MART 20MG TABLET if you are allergic to Telmisartan or any other ingredients of this medicine.
T MART 20MG TABLET should be taken with caution in patients having heart trouble or low blood pressure (due to dehydration problems, low-salt intake, diarrhoea or vomiting).
T MART 20MG TABLET is not recommended for use in children and adolescents (under 18 years of age).
T MART 20MG TABLET should be used with caution in elderly patients (aged 65 years and above).
Before taking T MART 20MG TABLET, inform your doctor if you have:
A. Drug-Drug interactions:
Before taking T MART 20MG TABLET, inform your doctor if you are taking any of the following medicines:
Overdosage:
If you or anyone else accidentally takes too much of T MART 20MG TABLET, consult your doctor immediately or visit the nearby hospital. The most common symptoms of overdose are low blood pressure, fast or slow heartbeat, dizziness, elevated levels of creatinine and sudden kidney failure.
Drug | : | Telmisartan |
Pharmacological Category | : | Angiotensin receptor blockers |
Therapeutic Indication | : | Essential hypertension, management of heart attack and stroke |
Dosage Forms | : | Tablet |
Disease description:
Essential hypertension is defined as persistently raised blood pressure (BP) with no secondary cause identified. The current definition of hypertension (HTN) is systolic blood pressure (SBP) values of 130 mm Hg or more and/or diastolic blood pressure (DBP) of more than 80 mm Hg.
Youtube link:
A: T MART 20MG TABLET can be considered as a drug of choice for high blood pressure. It contains Telmisartan which helps to relax the blood vessels and then normalize the blood pressure. Although, T MART 20MG TABLET can manage high blood pressure, you doctor might manage you with other drugs depending upon your condition.
A: Yes. T MART 20MG TABLET can make your heart to beat slow. If you experience any abnormally slow heart rate with shortness of breath, feeling of fainting and spinning sensation (vertigo) consult your doctor immediately.
A: Patients taking T MART 20MG TABLET must inform their doctor about their pre-existing disease conditions like kidney, heart or liver problems. Consult your doctor immediately if you experience any unusual symptoms after taking T MART 20MG TABLET.
A: Do not stop taking T MART 20MG TABLET without talking to your doctor first. Stopping this medicine suddenly can cause your blood pressure to spike and may increase the risk for heart attack or stroke.
A: T MART 20MG TABLET should be taken with caution in patients with kidney disease, kidney artery stenosis (narrowing of blood vessels to one or both the kidneys) and with a history of kidney transplant. Your doctor may assess your kidney functioning during management with this medicine to manage the risk of kidney damage or any unusual effects.
A: T MART 20MG TABLET does not manage high blood pressure but controls it. Your blood pressure may decrease during the first 2 weeks of management, but it may take 4 weeks for you to notice the full benefit of this medicine. Consult your doctor for the exact duration of recommendation for you.
1. KD. Tripathi. Drugs Affecting Renin Angiotensin System. Essentials of medical pharmacology. Eighth edition. 2019. Page – 535-538.
2. Philippe Gosse. A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours. NIH National Library of Medicine, National center for biotechnology information. PubMed Central. September 2006. [Accessed on 7th May 2022] click here
3. A Prem Kumar, Anirudra Ghorai, Vasudev Kriplani, Rabindra Kumar Dash, J Aravinda, Paramesh Shamanna, TK Sabeer, Abdul Hannan, and Santosh Revankar. Clinical data analysis of telmisartan for hypertension management in Indian population. NIH National Library of Medicine, National center for biotechnology information. PubMed Central June 2021. [Accessed on 7th May 2022] click here
4. Accord Healthcare Ireland Limited. Health Products Regulatory Authority (HPRA). [Revised in July 2021] [Accessed on 7th May 2022] click here
5. Hetero Labs Limited. U.S. Food & Drug Administration. [Revised in August 2015] [Accessed 7th May 2022] click here
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.